| Baseline | During chemotherapy (every cycle) | Follow-up after chemotherapy (month) | ||||
---|---|---|---|---|---|---|---|
0 | 1–8 | 6 | 12 | 18 | 24 | 36 | |
Enrolment | |||||||
 Informed consent | √ |  |  |  |  |  |  |
 Eligibility | √ |  |  |  |  |  |  |
General assessment | |||||||
 Age | √ |  |  |  |  |  |  |
 Sex | √ |  |  |  |  |  |  |
 Height | √ |  |  |  |  |  |  |
 Weight | √ | √ |  |  |  |  |  |
 Body surface area | √ |  |  |  |  |  |  |
 Surgical approach | √ |  |  |  |  |  |  |
 Chemotherapy regimen | √ |  |  |  |  |  |  |
 Chemotherapy strategy | √ |  |  |  |  |  |  |
 Pathological stage | √ |  |  |  |  |  |  |
 Molecular subtype | √ |  |  |  |  |  |  |
 ECOG PS | √ | √ | √ | √ | √ | √ | √ |
 EORTC QLQ-C30 | √ | √ |  |  |  |  |  |
 EORTC QLQ-BR23 | √ | √ |  |  |  |  |  |
 TCM constitution | √ | √ |  |  |  |  |  |
 Chest CT | √ |  |  | √ |  | √ | √ |
 *Breast MRI | √ |  |  | √ |  | √ | √ |
 Serum tumour biomarkers | √ | √ | √ | √ | √ | √ | √ |
Key evaluation | |||||||
 Blood routine test | √ | At least once per week | √ | √ | √ | √ | √ |
Safety examination | |||||||
 Urine routine test | √ | √ | √ | √ | √ | √ | √ |
 Liver function (ALT, AST, ALP, TBIL, GGT, etc.) | √ | √ | √ | √ | √ | √ | √ |
 Kidney function (CR, BUN, SCR, UA, etc.) | √ | √ | √ | √ | √ | √ | √ |
 Electrocardiogram | √ | √ | √ | √ | √ | √ | √ |
 Adverse events |  | √ | √ | √ | √ | √ | √ |
Data evaluation | |||||||
 Audit medical records |  | √ | √ | √ | √ | √ | √ |
 Ombudsman reviews medical records |  | √ | √ | √ | √ | √ | √ |
 Outcome measures |  | √ | √ | √ | √ | √ | √ |